SOBI

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Sobi gets EU okay for long-acting haemophilia A drug

The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any

News

Apellis drops ALS drug, in another blow to patients

The litany of failed experimental therapies for amyotrophic lateral sclerosis (ALS) added another verse today, after Apellis Pharma gave up on Sobi-partnered candidate peg

News

Sobi sizes up $1.7bn merger with blood cancer biotech CTI

Swedish Orphan Biovitrum (Sobi) has agreed a $1.7 billion merger deal to acquire CTI BioPharma and its recently-approved Vonjo drug for people with blood cancer myelofibro

News